Form 4: Recursion Pharma CEO Sells 100K Shares

Recursion Pharmaceuticals CEO Christopher Gibson sold 100,000 shares of Class A Common Stock for $5.70 per share, following a conversion from Class B shares, under a pre-arranged 10b5-1 trading plan.

Summary

• Christopher Gibson, CEO and Director of RECURSION PHARMACEUTICALS, INC. (RXRX), reported a transaction on October 23, 2025.
• The transaction involved the conversion of 100,000 shares of Class B Common Stock into 100,000 shares of Class A Common Stock.
• Immediately following the conversion, 100,000 shares of Class A Common Stock were sold at a price of $5.70 per share.
• This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Gibson on May 12, 2025.
• Following these transactions, Mr. Gibson directly beneficially owns 954,229 shares of Class A Common Stock and 4,923,334 shares of Class B Common Stock.
• He also indirectly owns additional Class B Common Stock through LAHWRAN-3 LLC (386,000 shares), LAHWRAN-4 LLC (388,000 shares), and the Gibson Family Trust (50,000 shares).
• Mr. Gibson holds several stock options with various exercise prices and vesting schedules, including 666,898 options at $10.09, 1,050,567 options at $7.25, 813,600 options at $8.55, 399,002 options at $11.4, 5,436 options at $11.4, and 282,500 options at $2.48.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While insider selling can be a concern, the fact that it was executed under a pre-arranged 10b5-1 plan mitigates some of the negative implications, suggesting a planned liquidity event rather than a reaction to adverse company news. However, it still represents a reduction in direct insider ownership.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned liquidity event rather than a reaction to new negative information.

Negatives

• The CEO sold a significant number of shares (100,000), which could be perceived negatively by investors as a reduction in insider ownership.

Risks

• Insider selling, even when pre-planned, can sometimes be interpreted by the market as a lack of confidence in the company's near-term prospects, potentially leading to negative share price pressure.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future financial performance or strategic direction.

Industry Context

This Form 4 filing details an insider transaction, which is a routine disclosure for publicly traded companies. It does not provide information directly related to broader industry trends or competitive landscape within the biotechnology or pharmaceutical sectors, but rather reflects an individual executive's equity management.

Stakeholder Impact

• Shareholders may interpret the insider sale differently; some may view it as a routine liquidity event, while others might see it as a signal of reduced confidence, potentially influencing investor sentiment.

Next Steps

• Ongoing vesting of various stock options held by the reporting person will continue according to their respective schedules.

Key Dates

Recommendation

The filing reports a pre-planned insider sale by the CEO, which is a routine event under a 10b5-1 plan. While insider selling can sometimes be a negative signal, the planned nature of this transaction suggests it's for personal financial management rather than a reaction to new company-specific information. The CEO still retains significant direct and indirect holdings, including substantial stock options. Therefore, this single transaction alone is not sufficient to warrant a strong buy or sell recommendation, and a 'hold' stance is appropriate as investors should consider broader company fundamentals and market conditions.

Keywords

Recursion Pharmaceuticals, RXRX, Christopher Gibson, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, CEO, Biotechnology, Pharmaceuticals